Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §3

Kisspeptin-10 — clinical evidence

Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.

Document identifier
CEI-MN-050/3
Series
Compound monograph
Version
2.2
Published
11 Jun 2025
Last reviewed
11 Jun 2025
Next review
11 Jun 2027
Identifier
10.71829/cei.mono.50
Certainty
Low
Cycle
2025 Q2

§3Clinical evidence

Assessed outcomes for Kisspeptin-10Point estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.20.40.60.81.0Standardised direction and relative magnitude of the recorded effectIndicationEffect as recordedGH axis0 trials · ModerateDiagnostic use as a probe of…Sexual dysfunction1 trial · LowSmall randomised crossover studies in…PCOS2 trials · LowKisspeptin-54 has been used as an…
Moderate or high certaintyLow or very low certainty
Figure 3. Illustrative. Assessed outcomes plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision, not the published confidence intervals. Published intervals appear in the per-indication extracts and in the text below.

§3.1Growth hormone deficiency and growth-hormone secretagogue pharmacology

Anchor outcome. Peak stimulated growth hormone.

Effect as recorded. Diagnostic use as a probe of hypothalamic-pituitary-gonadal function; —.[1,2]

Certainty. Moderate certainty The diagnostic application is the best-established use.

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment

§3.2Hypoactive sexual desire and erectile dysfunction

Anchor outcome. Female Sexual Function Index desire domain.

Effect as recorded. Small randomised crossover studies in men with hypoactive sexual desire reported changes in limbic activation on functional imaging and in behavioural measures; very small samples; imaging surrogate endpoints.[2,3]

Certainty. Low certainty Mechanistically interesting, clinically preliminary.

Contributing trials. KISS-PH2-HSDD. Full structured abstracts are published for each.

Full evidence extract for hypoactive sexual desire and erectile dysfunction · Indication assessment

§3.3Polycystic ovary syndrome

Anchor outcome. Change in body weight.

Effect as recorded. Kisspeptin-54 has been used as an oocyte-maturation trigger in assisted reproduction with reported reduction in ovarian hyperstimulation risk compared with human chorionic gonadotropin; small controlled studies; the decapeptide and the 54-residue peptide are not interchangeable.[3,4]

Certainty. Low certainty The assisted-reproduction work used kisspeptin-54, not the decapeptide. The Institute records this distinction because supply-side material routinely conflates them, exactly as it conflates thymosin beta-4 with TB-500.

Contributing trials. KISS-IVF-TRIGGER · KISS-DIAGNOSTIC. Full structured abstracts are published for each.

Full evidence extract for polycystic ovary syndrome · Indication assessment

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
  2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
  3. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
  4. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:10.1136/bmj.n71 · PMID 33782057

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Compound Evidence Institute · CEI-MN-050/3 · https://compoundevidence.com/monographs/kisspeptin-10/clinical-evidence/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.